is wegovy and glp 1 the same vs. Ozempic: Important Differences To Consider What Are the Side Effects

J Drugs Dermatol

The rationale for adding glucagon receptor agonism is the part that distinguishes it mechanistically

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status

Effectiveness : Because the approved weekly formulations rely on specific release mechanisms, changing the schedule may actually reduce appetite control the exact opposite of the intended effect